Recent Updates
Recently added Catalysts
CCM Positive Sentiment Score: 65/100

Concord Medical Announces Result of 2024 Annual General Meeting BEIJING

Key Takeaway: Concord Medical Services Holdings Limited has announced the results of its 2024 annual general meeting held on December 27, 2024. During the meeting, shareholders approved the adoption of the Fifth Amended and Restated Memorandum and Articles of Association, indicating a significant governance update. The company specializes in comprehensive cancer care and continues to focus on improving service quality and accessibility across China.

Market Sentiment Analysis

POSITIVE FACTORS

  • Concord Medical amended its Articles of Association, showing commitment to improving governance.
  • The company emphasizes enhancing quality and accessibility of cancer care in China.
  • Concord Medical features state-of-the-art technology like the proton therapy system for cancer treatment.

Full Press Release Details

Concord Medical Announces Result of 2024 Annual
BEIJING, January 6, 2025 /PRNewswire/ -- Concord Medical Services
Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specialized in cancer
treatment, research, education and prevention in China, today announced that it held its 2024 annual general meeting of shareholders on
December 27, 2024. At the meeting, the shareholders resolved by special resolution that amended and replaced the Fourth Memorandum
and Articles of Association of the Company then in effect by the adoption of the Fifth Amended and Restated Memorandum and Articles of
About Concord Medical
Concord Medical Services Holdings Limited is a
healthcare provider featuring a full cycle of premium oncology services including cancer diagnosis, treatment, education and prevention.
The Company focuses on providing multidisciplinary cancer care in all aspects of oncology healthcare services in its cancer hospitals
and equipping them with technologically advanced equipment such as the state-of-the-art proton therapy system. The Company is striving
to improve the quality and accessibility of cancer care through its network of self-owned cancer hospitals and clinics as well as partnered
hospitals across China. For more information, please see http://ir.ccm.cn.
Safe Harbor Statement
This announcement contains forward-looking statements.
These forward-looking statements can be identified by words or phrases such as "will," "expects," "anticipates,"
"future," "intends," "plans," "believes," "estimates" and similar expressions.
Forward-looking statements are inherently subject to uncertainties and contingencies beyond the Company's control and based upon
premises with respect to future business decisions, which are subject to change. A number of important factors could cause actual results
to differ materially from those contained in any forward-looking statement. The Company does not undertake any obligation to update any
forward-looking statement, except as required under applicable law.
For more information, please contact:
Concord Medical Services Holdings Limited

Frequently Asked Questions

When was Concord Medical's 2024 annual meeting held?

The 2024 annual meeting was held on December 27, 2024.

What significant resolution was passed at the meeting?

Shareholders adopted the Fifth Amended and Restated Memorandum and Articles.

What services does Concord Medical provide?

Concord Medical specializes in oncology services, including diagnosis and treatment.

What advanced technology does Concord Medical use?

The company utilizes a state-of-the-art proton therapy system for cancer treatment.

Where does Concord Medical operate its healthcare services?

The company operates across China through its own and partnered hospitals.

Last updated: Jan 6, 2025